Vera Therapeutics (VERA) Competitors $23.37 -0.63 (-2.63%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$23.88 +0.52 (+2.20%) As of 09:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA vs. BPMC, SRPT, AXSM, NUVL, VRNA, GRFS, KRYS, ADMA, CYTK, and ELANShould you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Verona Pharma (VRNA), Grifols (GRFS), Krystal Biotech (KRYS), ADMA Biologics (ADMA), Cytokinetics (CYTK), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Vera Therapeutics vs. Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Nuvalent Verona Pharma Grifols Krystal Biotech ADMA Biologics Cytokinetics Elanco Animal Health Vera Therapeutics (NASDAQ:VERA) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment. Do insiders & institutionals have more ownership in VERA or BPMC? 99.2% of Vera Therapeutics shares are held by institutional investors. 16.3% of Vera Therapeutics shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor VERA or BPMC? In the previous week, Blueprint Medicines had 5 more articles in the media than Vera Therapeutics. MarketBeat recorded 21 mentions for Blueprint Medicines and 16 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.42 beat Blueprint Medicines' score of 1.20 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Blueprint Medicines 14 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, VERA or BPMC? Vera Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Does the MarketBeat Community favor VERA or BPMC? Blueprint Medicines received 511 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 68.23% of users gave Blueprint Medicines an outperform vote while only 66.13% of users gave Vera Therapeutics an outperform vote. CompanyUnderperformOutperformVera TherapeuticsOutperform Votes4166.13% Underperform Votes2133.87% Blueprint MedicinesOutperform Votes55268.23% Underperform Votes25731.77% Is VERA or BPMC more profitable? Vera Therapeutics has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. Vera Therapeutics' return on equity of -50.13% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -50.13% -39.50% Blueprint Medicines -13.19%-77.49%-20.84% Which has preferable earnings and valuation, VERA or BPMC? Blueprint Medicines has higher revenue and earnings than Vera Therapeutics. Blueprint Medicines is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$95.99M-$2.75-8.50Blueprint Medicines$508.82M11.24-$67.09M-$1.08-82.87 Do analysts rate VERA or BPMC? Vera Therapeutics presently has a consensus target price of $64.67, indicating a potential upside of 176.71%. Blueprint Medicines has a consensus target price of $124.53, indicating a potential upside of 39.14%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Vera Therapeutics is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.20Blueprint Medicines 1 Sell rating(s) 6 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.68 SummaryVera Therapeutics beats Blueprint Medicines on 10 of the 18 factors compared between the two stocks. Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERA vs. The Competition Export to ExcelMetricVera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.49B$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-8.957.4422.4818.48Price / SalesN/A242.70395.10103.59Price / CashN/A65.8538.1834.62Price / Book12.056.516.774.25Net Income-$95.99M$143.21M$3.22B$248.23M7 Day Performance-0.43%1.98%1.50%0.89%1 Month Performance6.13%6.89%4.01%3.53%1 Year Performance-44.78%-2.52%16.16%5.08% Vera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERAVera Therapeutics2.9227 of 5 stars$23.37-2.6%$64.67+176.7%-40.9%$1.49BN/A-8.9540Upcoming EarningsNews CoveragePositive NewsBPMCBlueprint Medicines2.5598 of 5 stars$84.18-0.6%$124.95+48.4%-2.0%$5.38B$508.82M-77.94640Earnings ReportAnalyst ForecastNews CoveragePositive NewsSRPTSarepta Therapeutics4.7345 of 5 stars$55.23+2.7%$158.70+187.3%-50.7%$5.36B$1.90B44.18840AXSMAxsome Therapeutics4.8386 of 5 stars$103.00-1.4%$169.80+64.9%+52.2%$5.02B$385.69M-17.20380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsNUVLNuvalent1.891 of 5 stars$69.95-2.4%$115.50+65.1%+11.4%$5.01BN/A-20.1640Upcoming EarningsPositive NewsVRNAVerona Pharma2.8962 of 5 stars$60.07+2.0%$75.43+25.6%+366.5%$4.85B$42.28M-31.2930Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsGRFSGrifols3.8957 of 5 stars$7.01-1.0%N/A+8.1%$4.82B$7.21B5.9926,300Short Interest ↓Positive NewsKRYSKrystal Biotech4.9058 of 5 stars$161.91-4.0%$220.00+35.9%+10.9%$4.68B$290.52M54.15210Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsADMAADMA Biologics1.472 of 5 stars$19.64-7.8%$22.50+14.6%+265.0%$4.64B$426.45M70.14530Upcoming EarningsNews CoveragePositive NewsGap DownCYTKCytokinetics4.1729 of 5 stars$37.93-3.9%$81.63+115.2%-30.1%$4.52B$18.47M-7.05250Upcoming EarningsInsider TradeELANElanco Animal Health3.936 of 5 stars$8.48+0.5%$14.67+73.0%-28.0%$4.21B$4.44B21.209,800Upcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies Blueprint Medicines Competitors Sarepta Therapeutics Competitors Axsome Therapeutics Competitors Nuvalent Competitors Verona Pharma Competitors Grifols Competitors Krystal Biotech Competitors ADMA Biologics Competitors Cytokinetics Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VERA Stock Free VERA Stock Alerts